Table 2 Adverse events
Variable | CLL (n = 12) | DLBCL (n = 23) | FL (n = 13) | Overall (n = 48) |
|---|---|---|---|---|
Number of patients with at least one AE | 10 (83.3) | 18 (78.3) | 7 (53.8) | 35 (72.9) |
Number of AEs | 71 | 45 | 25 | 141 |
Number of deaths | 1 (8.3) | 0 | 1 (7.7) | 2 (4.2) |
Number of patients withdrawn from study due to an AE | 1 (8.3) | 0 | 0 | 1 (2.1) |
Number of patients with at least one | ||||
AE with fatal outcome | 1 (8.3) | 0 | 0 | 1 (2.1) |
SAE | 5 (41.7) | 3 (13.0) | 1 (7.7) | 9 (18.8) |
SAE leading to withdrawal from treatment | 1 (8.3) | 0 | 0 | 1 (2.1%) |
Related SAE | 4 (33.3) | 1 (4.3) | 1 (7.7) | 6 (12.5) |
AE leading to withdrawal from treatment | 1 (8.3) | 0 | 0 | 1 (2.1) |
AE leading to treatment interruption | 4 (33.3) | 3 (13.0) | 2 (15.4) | 9 (18.8) |
Related AE | 9 (75.0) | 12 (52.2) | 7 (53.8) | 28 (58.3) |
Related AE leading to treatment interruption | 4 (33.3) | 3 (13.0) | 2 (15.4) | 9 (18.8) |
Grade III–V AE (at greatest intensity) | 7 (58.3) | 5 (21.7) | 3 (23.1) | 15 (31.3) |